NCT03396315 - Bisphosphonates for Prevention of Post-Denosumab Bone Loss | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

June 9, 2023

Study Completion Date

June 9, 2023

Conditions

IOPOsteoporosis

Interventions

DRUG

Alendronate

oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis

DRUG

Zoledronic Acid

single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis

Trial Locations (2)

Columbia University Medical Center, New York

Creighton University, Omaha